Addex Therapeutics Ltd
ADXN
$5.89
-$0.01-0.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -99.19% | |||
| Total Other Revenue | -50.77% | -21.37% | |||
| Total Revenue | -51.52% | -68.06% | |||
| Cost of Revenue | -31.62% | -76.84% | |||
| Gross Profit | 23.11% | 79.27% | |||
| SG&A Expenses | -39.20% | 43.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.69% | 6.75% | |||
| Operating Income | 38.44% | -12.08% | |||
| Income Before Tax | 6.66% | -16.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.66% | -16.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.83% | -16.62% | |||
| EBIT | 38.44% | -12.08% | |||
| EBITDA | 38.44% | -12.09% | |||
| EPS Basic | 7.18% | -11.43% | |||
| Normalized Basic EPS | 7.38% | -11.93% | |||
| EPS Diluted | 7.18% | -11.43% | |||
| Normalized Diluted EPS | 7.38% | -11.93% | |||
| Average Basic Shares Outstanding | 0.55% | 4.62% | |||
| Average Diluted Shares Outstanding | 0.55% | 4.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||